세계의 고지혈증 치료제 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2033년)

Global Hyperlipidemia Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

US $ 3,920 ￦ 5,638,000

PDF & Excel (Single User License)

PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

US $ 4,730 ￦ 6,803,000

PDF & Excel (10-user License)

PDF 및 Excel 보고서를 동일 기업 내 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

US $ 7,430 ￦ 10,686,000

PDF & Excel (Corporate User License)

PDF 및 Excel 보고서를 동일 기업 내 모든 사용자가 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

한글목차

세계의 고지혈증 치료제 시장은 상당한 성장을 이루었으며, 2024년 261억 달러에서 2033년에는 363억 3,000만 달러에 달할 것으로 예측됩니다. 2025년부터 2033년까지 연평균 성장률(CAGR) 3.74%로 성장할 것으로 예측됩니다.

고지혈증 치료제 시장은 전 세계적으로 심혈관질환 및 대사 이상 유병률 증가에 힘입어 큰 폭으로 확대될 것으로 예상됩니다. PCSK9 억제제, RNA 기반 치료제, 신규 저분자 화합물 등 지질저하 치료제의 발전으로 효능과 안전성 프로파일이 개선되고 있습니다. 앞으로의 성장을 뒷받침하는 것은 유전자 분석과 바이오마커 분석에 기반하여 치료 요법을 조정하는 맞춤형 의료 접근법입니다. 환자 모니터링과 순응도를 위한 디지털 헬스 툴의 통합은 치료 결과를 개선하고 있습니다.

또한, 남아있는 심혈관 위험에 대처하기 위해 여러 지질 경로를 표적으로 하는 병용요법이 널리 보급되고 있습니다. 경구제와 지속형 주사제의 개발로 환자의 편의성과 순응도가 향상되고 있습니다. 의료 인프라에 대한 투자가 활발히 이루어지고 있는 신흥시장에서는 고지혈증 치료에 대한 접근성이 확대되고 있습니다. 새로운 표적과 기전이 밝혀짐에 따라 고지혈증 치료제 시장은 진화할 것이며, 심혈관질환의 이환율과 사망률을 낮출 수 있는 혁신적인 치료제가 제공될 것입니다.

목차

제1장 서문

제2장 주요 요약

• 시장 하이라이트
• 세계 시장 현황

제3장 고지혈증 치료제 - 산업 분석

• 소개 : 시장 역학
• 시장 성장 촉진요인
• 시장 성장 억제요인
• 시장 기회
• 업계 동향
• Porter's Five Forces 분석
• 시장 매력 분석

제4장 밸류체인 분석

• 밸류체인 분석
• 원재료 분석
  • 원재료 리스트
  • 원재료 제조업체 리스트
  • 주요 원재료 가격 동향
• 잠재적 바이어 리스트
• 마케팅 채널
  • 직접 마케팅
  • 간접 마케팅
  • 마케팅 채널 발전 동향

제5장 고지혈증 치료제 세계 시장 분석 : 유형별

• 유형별 개요
• 유형별, 과거 및 예측 데이터 분석
• 가족성
• 후천성

제6장 고지혈증 치료제 세계 시장 분석 : 약물 종류별

• 약물 종류별 개요
• 약물 종류별, 과거 및 예측 데이터 분석
• 스타틴
• 담즙산 분비 억제제
• 콜레스테롤 흡수 억제제
• 피브릭산 유도체
• PCSK9 억제제
• 배합제
• 기타 약물 종류별

제7장 고지혈증 치료제 세계 시장 분석 : 투여 경로별

• 투여 경로별 개요
• 투여 경로별, 과거 및 예측 데이터 분석
• 경구
• 비경구

제8장 고지혈증 치료제 세계 시장 분석 : 유통 채널별

• 개요 : 유통 채널별
• 유통 채널별, 과거 및 예측 데이터 분석
• 병원 약국
• 소매 약국
• 온라인 약국

제9장 고지혈증 치료제 세계 시장 분석 : 지역별

• 지역별 전망
• 소개
• 북미 매출 분석
  • 개요, 실적과 예측
  • 북미 : 부문별
  • 북미 국가별
  • 미국
  • 캐나다
  • 멕시코
• 유럽 매출 분석
  • 개요, 실적과 예측
  • 유럽 : 부문별
  • 유럽 국가별
  • 영국
  • 프랑스
  • 독일
  • 이탈리아
  • 러시아
  • 기타 유럽
• 아시아태평양 매출 분석
  • 개요, 실적과 예측
  • 아시아태평양 : 부문별
  • 아시아태평양 국가별
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주
  • 동남아시아
  • 기타 아시아태평양
• 라틴아메리카 매출 분석
  • 개요, 실적과 예측
  • 라틴아메리카 : 부문별
  • 라틴아메리카 국가별
  • 브라질
  • 아르헨티나
  • 페루
  • 칠레
  • 기타 라틴아메리카
• 중동 및 아프리카 매출 분석
  • 개요, 실적과 예측
  • 중동 및 아프리카 : 부문별
  • 중동 및 아프리카 국가별 리스트
  • 사우디아라비아
  • 아랍에미리트
  • 이스라엘
  • 남아프리카공화국
  • 기타 중동 및 아프리카

제10장 고지혈증 치료제 기업 경쟁 구도

• 고지혈증 치료제 시장 경쟁
• 제휴, 협력, 합의
• 인수합병
• 신제품 출시
• 기타 개발

제11장 기업 개요

• 상위 기업의 시장 점유율 분석
• 시장 집중도
• Johnson & Johnson
• Roche
• Pfizer
• Novartis
• Merck
• Sanofi
• Bristol Myers Squibb
• AstraZeneca
• GSK
• Eli Lilly And Company
• Amgen
• Regeneron
• Teva Pharmaceuticals
• Sun Pharma
• Dr. Reddy'S Laboratories

KSM

영문 목차

영문목차

Global Hyperlipidemia Drugs Market is poised to witness substantial growth, reaching a value of USD 36.33 Billion by the year 2033, up from USD 26.1 Billion attained in 2024. The market is anticipated to display a Compound Annual Growth Rate (CAGR) of 3.74% between 2025 and 2033.

The hyperlipidemia drugs market is set for significant expansion driven by rising prevalence of cardiovascular diseases and metabolic disorders worldwide. Advances in lipid-lowering therapies, including PCSK9 inhibitors, RNA-based therapeutics, and novel small molecules, are offering improved efficacy and safety profiles. Future growth will be supported by personalized medicine approaches that tailor treatment regimens based on genetic and biomarker analysis. The integration of digital health tools for patient monitoring and adherence is enhancing therapeutic outcomes.

Additionally, combination therapies targeting multiple lipid pathways are gaining traction to address residual cardiovascular risk. The development of oral formulations and long-acting injectables is improving patient convenience and compliance. Emerging markets with increasing healthcare infrastructure investments are expanding access to hyperlipidemia treatments. As research continues to uncover novel targets and mechanisms, the hyperlipidemia drugs market will evolve, delivering innovative therapies that reduce cardiovascular morbidity and mortality.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

LIST OF SEGMENTS COVERED

This section of the Hyperlipidemia Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

• Familial
• Acquired

By Drug Class

• Statins
• Bile Acid Sequestrants
• Cholesterol Absorption Inhibitors
• Fibric Acid Derivatives
• PCSK9 Inhibitors
• Combination
• Other Drug Classes

By Route of Administration

• Oral
• Parenteral

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• List of Companies Profiled in the report
• Johnson & Johnson, Pfizer, Roche, Merck & Co., Novartis, Sanofi, AstraZeneca, GSK, Bristol Myers Squibb, Eli Lilly, Amgen, Teva Pharmaceuticals, Regeneron, Alnylam Pharmaceuticals, Sun Pharma

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. HYPERLIPIDEMIA DRUGS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Type
  • 3.7.2 Market Attractiveness Analysis By Drug Class
  • 3.7.3 Market Attractiveness Analysis By Route of Administration
  • 3.7.4 Market Attractiveness Analysis By Distribution Channel
  • 3.7.5 Market Attractiveness Analysis By Regions

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL HYPERLIPIDEMIA DRUGS MARKET ANALYSIS BY TYPE

• 5.1. Overview By Type
• 5.2. Historical and Forecast Data Analysis By Type
• 5.3. Familial Historic and Forecast Sales By Regions
• 5.4. Acquired Historic and Forecast Sales By Regions

6. GLOBAL HYPERLIPIDEMIA DRUGS MARKET ANALYSIS BY DRUG CLASS

• 6.1. Overview By Drug Class
• 6.2. Historical and Forecast Data Analysis By Drug Class
• 6.3. Statins Historic and Forecast Sales By Regions
• 6.4. Bile Acid Sequestrants Historic and Forecast Sales By Regions
• 6.5. Cholesterol Absorption Inhibitors Historic and Forecast Sales By Regions
• 6.6. Fibric Acid Derivatives Historic and Forecast Sales By Regions
• 6.7. PCSK9 Inhibitors Historic and Forecast Sales By Regions
• 6.8. Combination Historic and Forecast Sales By Regions
• 6.9. Other Drug Classes Historic and Forecast Sales By Regions

7. GLOBAL HYPERLIPIDEMIA DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 7.1. Overview By Route of Administration
• 7.2. Historical and Forecast Data Analysis By Route of Administration
• 7.3. Oral Historic and Forecast Sales By Regions
• 7.4. Parenteral Historic and Forecast Sales By Regions

8. GLOBAL HYPERLIPIDEMIA DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 8.1. Overview By Distribution Channel
• 8.2. Historical and Forecast Data Analysis By Distribution Channel
• 8.3. Hospital Pharmacy Historic and Forecast Sales By Regions
• 8.4. Retail Pharmacy Historic and Forecast Sales By Regions
• 8.5. Online Pharmacy Historic and Forecast Sales By Regions

9. GLOBAL HYPERLIPIDEMIA DRUGS MARKET ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook
• 9.2. Introduction
• 9.3. North America Sales Analysis
  • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.3.2 North America By Segment Sales Analysis
  • 9.3.3 North America By Country Sales Analysis
  • 9.3.4 United States Sales Analysis
  • 9.3.5 Canada Sales Analysis
  • 9.3.6 Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.4.2 Europe By Segment Sales Analysis
  • 9.4.3 Europe By Country Sales Analysis
  • 9.4.4 United Kingdom Sales Analysis
  • 9.4.5 France Sales Analysis
  • 9.4.6 Germany Sales Analysis
  • 9.4.7 Italy Sales Analysis
  • 9.4.8 Russia Sales Analysis
  • 9.4.9 Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.5.2 Asia Pacific By Segment Sales Analysis
  • 9.5.3 Asia Pacific By Country Sales Analysis
  • 9.5.4 China Sales Analysis
  • 9.5.5 India Sales Analysis
  • 9.5.6 Japan Sales Analysis
  • 9.5.7 South Korea Sales Analysis
  • 9.5.8 Australia Sales Analysis
  • 9.5.9 South East Asia Sales Analysis
  • 9.5.10 Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.6.2 Latin America By Segment Sales Analysis
  • 9.6.3 Latin America By Country Sales Analysis
  • 9.6.4 Brazil Sales Analysis
  • 9.6.5 Argentina Sales Analysis
  • 9.6.6 Peru Sales Analysis
  • 9.6.7 Chile Sales Analysis
  • 9.6.8 Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.7.2 Middle East & Africa By Segment Sales Analysis
  • 9.7.3 Middle East & Africa By Country Sales Analysis
  • 9.7.4 Saudi Arabia Sales Analysis
  • 9.7.5 UAE Sales Analysis
  • 9.7.6 Israel Sales Analysis
  • 9.7.7 South Africa Sales Analysis
  • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE HYPERLIPIDEMIA DRUGS COMPANIES

• 10.1. Hyperlipidemia Drugs Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11. COMPANY PROFILES OF HYPERLIPIDEMIA DRUGS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Market Concentration Rate
• 11.3. Johnson & Johnson
  • 11.3.1 Company Overview
  • 11.3.2 Company Revenue
  • 11.3.3 Products
  • 11.3.4 Recent Developments
• 11.4. Roche
  • 11.4.1 Company Overview
  • 11.4.2 Company Revenue
  • 11.4.3 Products
  • 11.4.4 Recent Developments
• 11.5. Pfizer
  • 11.5.1 Company Overview
  • 11.5.2 Company Revenue
  • 11.5.3 Products
  • 11.5.4 Recent Developments
• 11.6. Novartis
  • 11.6.1 Company Overview
  • 11.6.2 Company Revenue
  • 11.6.3 Products
  • 11.6.4 Recent Developments
• 11.7. Merck
  • 11.7.1 Company Overview
  • 11.7.2 Company Revenue
  • 11.7.3 Products
  • 11.7.4 Recent Developments
• 11.8. Sanofi
  • 11.8.1 Company Overview
  • 11.8.2 Company Revenue
  • 11.8.3 Products
  • 11.8.4 Recent Developments
• 11.9. Bristol Myers Squibb
  • 11.9.1 Company Overview
  • 11.9.2 Company Revenue
  • 11.9.3 Products
  • 11.9.4 Recent Developments
• 11.10. AstraZeneca
  • 11.10.1 Company Overview
  • 11.10.2 Company Revenue
  • 11.10.3 Products
  • 11.10.4 Recent Developments
• 11.11. GSK
  • 11.11.1 Company Overview
  • 11.11.2 Company Revenue
  • 11.11.3 Products
  • 11.11.4 Recent Developments
• 11.12. Eli Lilly And Company
  • 11.12.1 Company Overview
  • 11.12.2 Company Revenue
  • 11.12.3 Products
  • 11.12.4 Recent Developments
• 11.13. Amgen
  • 11.13.1 Company Overview
  • 11.13.2 Company Revenue
  • 11.13.3 Products
  • 11.13.4 Recent Developments
• 11.14. Regeneron
  • 11.14.1 Company Overview
  • 11.14.2 Company Revenue
  • 11.14.3 Products
  • 11.14.4 Recent Developments
• 11.15. Teva Pharmaceuticals
  • 11.15.1 Company Overview
  • 11.15.2 Company Revenue
  • 11.15.3 Products
  • 11.15.4 Recent Developments
• 11.16. Sun Pharma
  • 11.16.1 Company Overview
  • 11.16.2 Company Revenue
  • 11.16.3 Products
  • 11.16.4 Recent Developments
• 11.17. Dr. Reddy'S Laboratories
  • 11.17.1 Company Overview
  • 11.17.2 Company Revenue
  • 11.17.3 Products
  • 11.17.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of privcompanies

관련자료